UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 17, 2015
Esperion Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
| 001-35986 |
| 26-1870780 |
(State or other jurisdiction of |
| (Commission File Number) |
| (I.R.S. Employer |
3891 Ranchero Drive, Suite 150 Ann Arbor, MI |
| 48108 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (734) 887-3903
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On March 17, 2015, Esperion Therapeutics, Inc. issued a press release titled, “Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002 Added to Stable Statin Therapy in Patients with Hypercholesterolemia” (the “Press Release”). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press Release dated March 17, 2015. |
* * *
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 17, 2015 |
| Esperion Therapeutics, Inc. | |
|
|
| |
|
| By: | /s/ Tim M. Mayleben |
|
|
| Tim M. Mayleben |
|
|
| President and Chief Executive Officer |